Direct oral anticoagulants and the risk of major bleeding in patients with non-valvular atrial fibrillation (Q17-01)

Direct oral anticoagulants and the risk of major bleeding in patients with non-valvular atrial fibrillation (Q17-01)

Q17-01

Overview

What is the issue?
  • Vitamin K antagonists (warfarin) have been the first line of anticoagulation therapy for AF for years; however, direct oral anticoagulants (DOACs) are progressively replacing warfarin. Information on the real world safety and effectiveness of DOACs is needed.
  • This project is an international collaboration with the European Medicines Agency (EMA).
What was the aim of the study?
  • To establish the risk of major bleeding in direct oral anticoagulant (DOAC) users versus vitamin K antagonist (VKA) users, using health care databases from four European countries and six provinces in Canada.

Manuscripts

Van den Ham HA, Souverein PC, Klungel OH, Platt RW, Ernst P, Dell’Aniello S, Schmiedl S, Rottenkolber M, Huerta C, Martín Merino E, León-Muñoz LM, Montero D, Andersen M, Aakjær M, De Bruin M, Gardarsdottir H. Major bleeding in users of direct oral anticoagulants in atrial fibrillation: a pooled analysis of results from multiple population-based cohort studies. Pharmacoepidemiol Drug Saf. 2021 Oct;30(10):1339-1352.

Presentations

Project Team

Methods Lead
Robert W. Platt PhD
Research Assistant
Carolina Moriello MSc
Site Investigator
Hala Tamim PhD
Atlantic
Site Investigator
Jacques LeLorier MD, MSc, FRCPC, FISPE
Quebec
Site Investigator
Michael Paterson MSc
Ontario
Site Investigator
Colin R. Dormuth ScD
British Columbia
Analyst
Nianping Hu PhD
Saskatchewan
Analyst
Anjie Huang
Ontario
Analyst
Yan Wang MSc
Atlantic
Analyst
Matthew Dahl BSc
Manitoba
Analyst
Greg Carney BSc, PhD
British Columbia
Analyst
Jianguo (James) Zhang MSc
Alberta